Coronavirus: US authorises Moderna, Pfizer/BioNTech vaccine boosters retooled for Omicron variants
- Until now, Covid-19 vaccines targeted the original coronavirus strain, even as wildly different mutants emerged
- The FDA’s Dr Peter Marks said a vaccine matched to currently spreading variants might do a better job fighting infection, not just serious illness
The move by the Food and Drug Administration (FDA) tweaks the recipe of shots made by Pfizer and rival Moderna that already have saved millions of lives. The hope is that the modified boosters will blunt yet another winter surge.
“You’ll see me at the front of the line,” FDA vaccine chief Dr. Peter Marks said soon before his agency cleared the new doses.
The combination aims to increase cross-protection against multiple variants.
“It really provides the broadest opportunity for protection,” Pfizer vaccine chief Annaliesa Anderson said.
The updated boosters are only for people who have already had their primary vaccinations, using the original vaccines.
Doses made by Pfizer and its partner BioNTech are for anyone 12 and older while Moderna’s updated shots are for adults – if it has been at least two months since their last primary vaccination or their latest booster. They’re not to be used for initial vaccinations.
There’s one more step before a fall booster campaign begins: The Centres for Disease Control and Prevention (CDC) must recommend who should get the additional shot. An influential CDC advisory panel will debate the evidence on Thursday – including whether people at high risk from Covid-19 should go first.
“As we head into fall and begin to spend more time indoors, we strongly encourage anyone who is eligible to consider receiving a booster dose with a bivalent Covid-19 vaccine to provide better protection against currently circulating variants,” FDA Commissioner Dr. Robert Califf said in a statement.
The US has bought more than 170 million doses from the two companies. Pfizer said it could ship up to 15 million of those doses by the end of next week.
The big question is whether people weary of vaccinations will roll up their sleeves again. Just half of vaccinated Americans got the first recommended booster dose, and only a third of those 50 and older who were urged to get a second booster did so.
It’s time for US authorities to better explain that the public should expect an updated Covid-19 vaccination every so often, just like getting a fall flu shot or a tetanus booster after stepping on a rusty nail, said University of Pennsylvania immunologist E. John Wherry.
“We need to rebrand it in a societally normal-looking way,” rather than a panicked response to new mutants, Wherry said. “Give a clear, forward-looking set of expectations.”
Here’s the rub: The original vaccines still offer strong protection against severe disease and death from Covid-19 for most generally healthy people, especially if they got that important first booster dose. It’s not clear just how much more benefit an updated booster will bring – beyond a temporary jump in antibodies capable of fending off an Omicron infection.
One reason: The FDA cleared the modifications ahead of studies in people, a step toward eventually handling Covid-19 vaccine updates more like yearly flu shots.
First, FDA checked human studies of earlier Pfizer and Moderna attempts to update their vaccines – shots matching the Omicron strain that struck last winter.
That recipe change was safe, and substantially boosted antibodies targeting the earlier variant – better than another dose of the original vaccine – while adding a little protection against today’s genetically distinct BA.4 and BA.5 Omicron versions. The BA.5 subvariant currently accounts for more than 88 per cent of US infections.
But FDA ordered the companies to brew even more up-to-date doses that target those newest Omicron mutants instead, sparking a race to roll out shots in less than three months. Rather than waiting a few more months for additional human studies of that recipe tweak, Marks said animal tests showed the latest update spurs “a very good immune response”.
The hope, he said, is that a vaccine matched to currently spreading variants might do a better job fighting infection, not just serious illness, at least for a while.
What’s next? Even as modified shots roll out, Moderna and Pfizer are conducting human studies to help assess their value, including how they hold up if a new mutant comes along.
And for children, Pfizer plans to ask FDA to allow updated boosters for 5- to 11-year-olds in early October.
It’s the first US update to the Covid-19 vaccine recipe, an important but expected next step – like how flu vaccines get updated every year.
Additional reporting by Reuters